Literature DB >> 6249691

Impaired T cell function and decreased natural killer activity in patients with liver cirrhosis and their significance in the development of hepatocellular carcinoma.

T Morizane, T Watanabe, K Tsuchimoto, M Tsuchiya.   

Abstract

It is well known that the incidence of hepatocellular carcinoma (HCC) in patients with liver cirrhosis (LC) is very high. We investigated the immunological state in patients with LC and HCC. T cell population of peripheral blood lymphocytes (PBL) and blast transformation of PBL by phytohaemagglutinin (PHA) were significantly decreased in patients with LC. Natural killer activity against HeLa cell was also significantly decreased in these patients. These results suggest that immunological surveillance is impaired in patients with LC and this may be one of the aetiological factors in genesis of hepatocellular carcinoma in patients with LC.

Entities:  

Mesh：

Year:  1980        PMID： 6249691     DOI： 10.1007/bf02774272

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN： 0435-1339


  30 in total

1.  Primary and metastatic carcinoma of the liver. Relationship to hepatic cirrhosis.

Authors:  E A GALL
Journal:  Arch Pathol       Date:  1960-08

2.  Specificities in natural cell-mediated cytotoxicity by the cross-competition assay.

Authors:  M Takasugi; D Koide; A Ramseyer
Journal:  Int J Cancer       Date:  1977-03-15       Impact factor: 7.396

3.  In vitro induction of tumor specific immunity: requirements for T lymphocytes and tumor growth inhibition in vivo.

Authors:  M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1973-08       Impact factor: 5.532

4.  Cytotoxicity against tumour-associated antigens not H-2 restricted.

Authors:  H T Holden; R B Herberman
Journal:  Nature       Date:  1977-07-21       Impact factor: 49.962

5.  Primary liver cell cancer in Britain--a viral aetiology?

Authors:  M F Bassendine; R G Chadwick; T Lyssiotis; H C Thomas; S Sherlock; B J Cohen
Journal:  Br Med J       Date:  1979-01-20

6.  Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens.

Authors:  G Janossy; M F Greaves
Journal:  Clin Exp Immunol       Date:  1971-10       Impact factor: 4.330

7.  Role of non-conventional natural killer cells in resistance against syngeneic tumour cells in vivo.

Authors:  O Haller; M Hansson; R Kiessling; H Wigzell
Journal:  Nature       Date:  1977-12-15       Impact factor: 49.962

8.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

9.  Inhibition of leukocyte migration by tumor-associated antigen in soluble extracts of human hepatoma.

Authors:  C Lee; S Chen; T Lin
Journal:  Cancer Res       Date:  1977-03       Impact factor: 12.701

10.  Specific immunodiagnosis of hepatocellular carcinoma by leucocyte adherence inhibition.

Authors:  W J Halliday; J W Halliday; C B Campbell; A E Maluish; L W Powell
Journal:  Br Med J       Date:  1974-05-18
View more
  4 in total

1.  Natural killer activity in patients with chronic hepatitis treated with OK432, interferon, adenine arabinoside and glycyrrhizin.

Authors:  T Wada; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-06

2.  The indications for tumor mass reduction surgery and subsequent multidisciplinary treatments in stage IV hepatocellular carcinoma.

Authors:  M Yamamoto; H Iizuka; M Matsuda; K Nagahori; K Miura; J Itakura
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

Review 3.  NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.

Authors:  Cheng Sun; Haoyu Sun; Cai Zhang; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2014-10-13       Impact factor: 11.530

Review 4.  A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer.

Authors:  Lenneke A M Cornelissen; Sandra J Van Vliet
Journal:  Biomolecules       Date:  2016-05-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.